Low-value approvals and high prices might incentivize ineffective drug development Journal Article
| Authors: | Prasad, V.; McCabe, C.; Mailankody, S. |
| Article Title: | Low-value approvals and high prices might incentivize ineffective drug development |
| Abstract: | Drug regulators' acceptance of any statistically significant improvement shown in a single randomized trial and lofty drug prices has created a situation where it is now, hypothetically, profitable for a company to run a clinical trials portfolio of chemically inert compounds. While the current cancer drug pipeline is certainly superior to inert drugs, we must rethink market incentives to encourage transformational drug development. © 2018 Macmillan Publishers Ltd., part of Springer Nature. |
| Keywords: | overall survival; sunitinib; drug efficacy; liver cell carcinoma; drug approval; united states; disease free survival; antineoplastic agent; progression free survival; food and drug administration; renal cell carcinoma; mathematical model; neuroendocrine tumor; drug cost; reimbursement; everolimus; neratinib; drug industry; profit; human epidermal growth factor receptor 2 positive breast cancer; human; priority journal; article |
| Journal Title: | Nature Reviews Clinical Oncology |
| Volume: | 15 |
| Issue: | 7 |
| ISSN: | 1759-4774 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2018-07-01 |
| Start Page: | 399 |
| End Page: | 400 |
| Language: | English |
| DOI: | 10.1038/s41571-018-0030-2 |
| PROVIDER: | scopus |
| PUBMED: | 29760505 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 August 2018 -- Source: Scopus |
